DF-CONSORT

Development of a CONSORT Extension for Early Phase Dose-finding Trials CONSORT Extension (DF-CONSORT)

Protocol
Version: 1.0
Dated: 12/08/2021

Chief Investigator: Professor Christina Yap
Sponsor: The Institute of Cancer Research
Funders: National Institute for Health Research/Medical Research Council
Coordinating Trials Unit: ICR Clinical Trials and Statistics Unit (ICR-CTSU)
The Institute of Cancer Research

<table>
<thead>
<tr>
<th>ICR-CTSU Protocol Number</th>
<th>ICR-CTSU/2021/10076</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor Reference Number</td>
<td>CCR5460</td>
</tr>
<tr>
<td>MRC Reference Number</td>
<td>MR/T044934/1</td>
</tr>
</tbody>
</table>

This protocol is a controlled document and should not be copied, distributed or reproduced without the written permission of the ICR-CTSU
Scientific Coordination

Chief Investigator
Professor Christina Yap, ICR-CTSU

Clinical Trials Programme Manager
Aude Espinasse, ICR-CTSU.

Trial Methodologist
Dr Olga Solovyeva, ICR-CTSU

Protocol Development Group:
Professor Christina Yap, Institute of Cancer Research
Ms Aude Espinasse, Institute of Cancer Research
Dr Olga Solovyeva, Institute of Cancer Research
Professor Adrian Mander, Cardiff University
Dr Alun Bedding, Roche
Mr Andrew Kightley, Patient and Public Involvement lead.
Professor Christopher Weir, University of Edinburgh
Professor Jeff Evans, University of Glasgow
Professor Johann De Bono, Institute of Cancer Research
Dr Munyaradzi Dimairo, University of Sheffield.
Dr Rong Liu, Bristol Meyers Squibb
Dr Sally Hopewell, Oxford University
Professor Thomas Jaki, Lancaster University/University of Cambridge
Contents

Glossary ................................................................................................................................................ 55

1 Introduction ........................................................................................................................................... 77
  1.1 Background ................................................................................................................................ 77
  1.2 Reporting quality in early phase dose-finding trials ................................................................. 77

2 Aims and objectives: ........................................................................................................................... 88

3 Scope and General Principles ........................................................................................................... 99
  3.1 Scope ......................................................................................................................................... 99
  3.2 Principles .................................................................................................................................. 1010

4 Study Management and membership ............................................................................................ 1040
  4.1 Establishment of an International Executive Committee and Independent Expert Panel 1040

5 Methodology ...................................................................................................................................... 1112
  5.1 Stage one: Draft checklist generation ......................................................................................... 1112
    5.1.1 Rapid Scoping Review ......................................................................................................... 1112
    5.1.2 Candidate Item Generation ................................................................................................. 1242
  5.2 Stage two: Delphi Survey ........................................................................................................... 1242
    5.2.1 Identification of participants ............................................................................................... 1243
    5.2.2 Consent, withdrawal and confidentiality .............................................................................. 1434
    5.2.3 Sample size ......................................................................................................................... 1434
    5.2.4 Scoring ................................................................................................................................ 1544
    5.2.5 Software ............................................................................................................................. 1544
    5.2.6 Survey administration ......................................................................................................... 1545
    5.2.7 Pilot .................................................................................................................................... 1545
    5.2.8 Analysis ............................................................................................................................... 1545
    5.2.9 Stopping Criteria .................................................................................................................. 1646
  5.3 Stage 3: Consensus Meeting: ....................................................................................................... 1747
    5.3.1 Objectives ............................................................................................................................ 1747
    5.3.2 Definition of Consensus ...................................................................................................... 1747
    5.3.3 Identification of participants ............................................................................................... 1747
    5.3.4 Consensus meeting activities ............................................................................................. 1747
  5.4 Stage 4: Development of a reporting guidance and explanatory support document .......... 1748
    5.4.1 Guideline development process .......................................................................................... 1848
    5.4.2 Piloting the guideline .......................................................................................................... 1848

6 Stage 5: Dissemination plan ............................................................................................................. 1848

7 Ethics approval .................................................................................................................................. 1949

8 Funding and any additional support ............................................................................................... 1949
All members declare that they have no conflict of interest to disclose.
Glossary

**Basket Trial**: A type of clinical trial that tests how well a new drug or other substance works in patients who have different types of cancer that all have the same mutation or biomarker. In basket trials, patients all receive the same treatment that targets the specific mutation or biomarker found in their cancer.

**Cohen’s kappa coefficient (κ)**: A statistic used to measure inter-rater reliability (and also intra-rater reliability) for qualitative (categorical) items

**CONSORT**: Consolidated Standards of Reporting Trials. It encompasses various initiatives developed by the CONSORT Group to alleviate the problems arising from inadequate reporting of randomised controlled trials.

**Delphi Survey**: A Delphi Survey is a series of questionnaires administered sequentially that allow experts to develop ideas about potential future developments around an issue. The questionnaires are developed throughout the process in relation to the responses given by participants.

**Dose**: Quantity of a medicine (e.g. drug or radiotherapy) to be administered or extent to which a patient may be exposed to a therapy.

**Dose-finding trial**: Early Phase trial where increasing doses/regimens of the investigated therapy are administered to sequential groups of patients, with interim assessments of the safety/tolerability and activity of the treatment.

**Dose limiting toxicity**: Side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.

**Drug Schedule/Regimen**: Definition of the dose, frequency, mode of administration and duration for a specific treatment.

**E&E**: Elaboration and Explanation

**Expansion cohort**: A phase in a clinical trial that aims to accrue additional patients, after an initial dose-escalation component, with different or targeted eligibility criteria in order to collect additional information on safety or activity.

**FDA**: Food and Drug Administration, the US regulatory authority for Clinical Trials

**Maximum tolerated dose**: The highest dose of a drug or treatment that does not cause unacceptable side effects.

**MHRA**: Medicine and Healthcare Products Regulatory Agency, the UK regulatory authority for Clinical Trials.

**PD**: Pharmacodynamics, described as what a drug does to the body, refers to how the drug works and how it affects the body.

**Phase 0 trial**: Phase 0 trials use only a few small doses of a new drug in a few people, without therapeutic intent. They aim at proving the drug behaves as expected in pre-clinical studies.

**Platform trial**: A type of clinical trial with an open master protocol, which allows for multiple treatments to enter or exit the trial over the course of the study.

**PK**: Pharmacokinetics, sometimes described as what the body does to a drug, refers to the movement of drug into, through, and out of the body. PK includes the analysis of chemical metabolism and the measurement/modelling of a substance from the moment that it is administered up to the point at which it is completely eliminated from the body.

**Recommended Phase 2 Dose (RP2D)**: Dose of a drug or treatment recommended to be taken forward for phase II trials following a dose finding study.

**SD**: Standard Deviation – measure of how spread a set of values under consideration are.

**Umbrella trial**: A type of clinical trial that tests how well new drugs or other substances work in patients who have the same type of cancer but different gene mutations (changes) or biomarkers. In
umbrella trials, patients receive treatment based on the specific mutation or biomarker found in their cancer.

**Window of opportunity trial:** trial which allows a drug (or other intervention) of interest to be given to a patient over a short period of time, usually 2—4 weeks, prior to the instigation of standard therapy.
1 Introduction

1.1 Background

Often termed “Dose-finding” or “Dose escalation” studies, early phase trials (Phase I or Phase I/II) conducted in healthy volunteers or patients and including interim dose decisions are a critical step in therapy development. Results from dose-finding trials, such as drug disposition (absorption, distribution, metabolism and excretion), adverse effects, exposure, Pharmacodynamics (PD) biomarker activity and clinical activity, directly influence decisions on further therapy development and ultimately whether the selected dose(s) can be confirmed as safe and efficacious.

Poorly reported dose-finding trials with inadequate rigour may lead to bias in reporting and lack of reproducibility. This runs the risk of progressing study treatments (e.g. pharmacotherapies or radiotherapy) to subsequent later phase studies with a false sense of their proven safety and activity, and with inappropriate dosing regimens that may become fixed for the duration of the life cycle of that treatment. The converse may also occur – the inappropriate discontinuation of a potentially safe or efficacious treatment. This wastes time and resources, but more importantly, may unethically expose participants to ineffective or even harmful interventions[1].

This is particularly relevant as a considerable number of early phase trials are sponsored and run by academic institutions or publicly funded National Health Service (NHS) Trusts, with funding from non-commercial sources including Research Councils and medical charities (e.g. Cancer Research UK). In the UK, 159 out of 1157 (14%) Phase I clinical trials, which started in 2014-2018, had non-industry sponsors (data from ClinicalTrials.gov). This emphasises the importance of this research to public research institutions and industry alike.

Based on results from ClinicalTrials.gov of trials in all countries, there are substantially more Phase I trials than Phase III trials – 46% more (13826 versus 9501 of trials, which started in 2014-2018). Data from pharmaceutical trials in the US in 2004-2012 show that the estimated average cost of a Phase I trial across all therapeutic areas ranged from US $1.4 to 6.6 million [2]; such high costs reinforces the importance of managing resources efficiently. Poor dose selection can lead to failed trials in Phase II (> 80% attrition from Phase I) or Phase III (around 50% attrition from Phase II); or unsuccessful regulatory submissions or dose changes post-approval due to excessive toxicities or lack of efficacy[3].

1.2 Reporting quality in early phase dose-finding trials

More than 580 biomedical journals now require that trial reports conform to the CONSORT 2010 reporting guidelines for randomised parallel group clinical trials or an appropriate CONSORT extension to improve transparency, reproducibility, consistency and accuracy in reporting [4, 5]. Endorsement of the CONSORT guidelines is usually demonstrated by a statement in a journal’s “Instructions to Authors” indicating support or a recommendation or requirement for authors to adhere to the CONSORT checklist when submitting a manuscript of a randomised trial for publication consideration [6]. A systematic review, based on more than 16,000 trials, published in 2012 showed that journal endorsement of the CONSORT guidelines was associated with more completely reported randomised trials [7].

A consensus-driven CONSORT guideline does not exist for the reporting of early phase dose-finding trials (as defined in Section 3.1). Hence, reporting standards are often poor, given the challenges in reporting the findings of potentially complex early phase trial designs. Incomplete, unclear, or inaccurate reporting of the design, conduct and analysis of trials can hinder interpretability, reproducibility and impact on timely clinical development, and lead to erroneous conclusions on safety and efficacy. For example, vital information such as trial design, key outcomes and analysis
populations used for dosing decisions and pre-planned dosing decision criteria should be included, to allow readers to interpret the trial findings accurately.

Most early phase dose-findings trials are non-randomised, and therefore it is likely that many have not used the CONSORT 2010 guidance though many of its reporting items would be applicable. There is a need to extend the CONSORT guidance for dose-finding trials, to produce a robust and comprehensive consensus-driven guidance, incorporating their unique features, that is applicable across all early phase dose-finding trials (regardless of the specific trial design that has been implemented or disease area).

2 Aims and objectives:

The overall aim of this research is to develop and disseminate to stakeholders an extension to the CONSORT 2010 statement tailored to the specific requirements of early phase dose-finding clinical trials across all disease areas.

Specific core objectives are as follows:

(a) Identify the gaps in reporting of dose-finding trials and to inform objective (b) through a rapid scoping review of the literature.
(b) Generate potential reporting items through review of existing dose-finding trials guidance, the results of the rapid scoping review in (a), and expert opinions.
(c) Conduct Delphi surveys to gather perceptions of key stakeholders on the importance of the drafted reporting items and to suggest additional items.
(d) Conduct consensus exercise to review Delphi survey findings and draw recommendations on essential reporting items that should be included in the final CONSORT extension checklist and other aspects that should be addressed in the explanation and elaboration (E&E) document.
(e) Finalise the reporting statement and supporting documentation including the E&E document. We will pilot-test the near-final guidelines with real-world examples to identify any gaps, and incorporate feedback to the final revision.
(f) Disseminate the CONSORT extension statement and maximise engagement of stakeholders, including patient and public engagement through patient and public involvement (PPI) led activities, in particular the production of two PPI lay summaries.

This guideline is anticipated to serve as a useful resource for trialists, journal editors, peer reviewers, funders, regulators, and research ethics committees to promote best practice in the reporting of early phase dose-finding trials. To achieve these objectives, the dose-finding CONSORT Executive Committee will follow gold standard methods for developing healthcare reporting guidelines recommended by the CONSORT group (4, 8).

It is anticipated that the guidance will result in:

- Improving the transparency and adequacy reporting of the reporting of early phase dose-finding trials,
- Enhancing reproducibility of methods,
- Enhancing the interpretability of early phase dose-finding trials results,
- Providing a framework for peer review of early phase dose-finding trial reports,
- Indirectly helping researchers in designing early phase dose-finding trials,
• As a result of the above points, the generated guidance will ultimately benefit the overall clinical research community in contributing to reducing research waste, as well as patients.

3 Scope and General Principles

This CONSORT statement extension is intended to be used across a range of disease and therapeutic areas. Additionally, terms like “early phase” and “dose-finding” can often be used in slightly different ways. As a result, it is important to clarify the scope of the project, and the trials that it intends to cover as well as the general principles underpinning the project.

3.1 Scope

• Our focus is on early phase clinical trials (typically referred to as Phase I with or without dose expansion cohorts or Phase I/II), where interim dose-decisions are taken using accumulating trial data to either escalate, de-escalate, stay at the current level or stop a trial early. The dose assignment decisions could be based on a/ safety, b/ PK or biological markers or c/a combination of these parameters. The aim of the trial is to determine the safety profile of the intervention and/or to identify a recommended dosing regimen (including radiotherapy, e.g. chemo-radiation studies or studies to escalate dose and/or intensity of fractionation).

• The guidance applies to all early phase dose-escalation (or de-escalation) clinical trials where more than one ascending (or descending) dosing regimens are investigated sequentially. This could be:
  • intra-participant escalation (where doses are increased sequentially over time within a participant),
  • inter-participant escalation (where each participant is allocated a specific dose and doses are increased sequentially over time for subsequent participants),
  • or both.

• Although this guidance does not specifically address the reporting needs of early phase trials that do not include interim dose decisions taken sequentially (e.g. trials with safety run-ins where only one dose is assessed for safety), some principles covered here may still apply to such trials.

• It excludes clinical trials which randomise patients simultaneously to several dosing regimens, without any initial sequential dose-decision evaluation, sometimes referred to as dose-ranging trials. Dose-ranging trials with adaptations are covered by Adaptive designs CONSORT Extension (ACE). Dose ranging trials without adaptations are covered by CONSORT 2010, and other relevant extensions such as multi-arm trials.

• Trials where the dose-finding element is only a part of the whole trial in one or more experimental arms / disease groups (e.g. in basket, umbrella, platform trials or master protocols) are included.

• The guideline does not primarily address specific reporting needs for Phase 0/window of opportunity trials, phase II/III, food-effect or feasibility trials or animal studies, which incorporate interim dose-decisions, but some principles covered here may still apply to such trials.
3.2 Principles

- DF-CONSORT covers general reporting principles to make it applicable to a wide range of current and future dose-finding trials in all disease settings and participant population (encompassing both adults and paediatric), which evaluate sequential dosing regimens in one or more interventional treatments.

- It presents the *minimum* essential requirements that should be reported but we also encourage authors to report additional information that may enhance the interpretation of trial findings.

- It intends to provide generic reporting guidelines relevant to all dose-finding designs, not to legitimize or discourage any particular dose-finding design, trial adaptation, underpinning methods (model or rule-based) or statistical framework used (frequentist or Bayesian methods).

- It aims to promote transparent and adequate reporting of dose-finding trials to maximise their potential benefits and improve the interpretability of their results and their reproducibility, without impeding their appropriate use or stifling design innovation. Therefore, the guideline does not specifically address the appropriateness of adaptive statistical methods.

- Access to information is most important regardless of the source and form of publication. For example, use of appendices and citation of accessible material (such as protocols, statistical analysis plans (SAPs), or related publications) is sufficient.

- The order in which researchers report information does not necessarily need to follow the order of the checklist.

4 Study Management and membership

4.1 Establishment of an International Executive Committee and Independent Expert Panel

To support the development of the guidelines, and increase impact and uptake, an international Executive Committee has been formed, comprising of a multi-disciplinary team of international statistical methodologists and trialists (clinicians and statisticians conducting trials) in early phase trials in both academia and pharmaceutical industry, a CONSORT group representative and a patient and public representative. The Executive Committee will meet every 2-3 months to discuss progress and specific aspects of the project as required. The members of the Executive committee are:

- Professor Christina Yap, Institute of Cancer Research
- Dr Munyaradzi Dimairo, University of Sheffield
- Professor Christopher Weir, University of Edinburgh
- Professor Adrian Mander, Cardiff University
- Professor Thomas Jaki, Lancaster University / University of Cambridge
- Professor Jeff Evans, University of Glasgow
- Dr Rong Liu, Bristol-Myers Squibb
• Dr Shing Lee, Columbia University
• Andrew Kightley, Patient and Public Involvement lead
• Dr Sally Hopewell, University of Oxford
• Professor Johann de Bono, Institute of Cancer Research
• Dr Alun Bedding, Roche.

In order to expedite the decision-making process, designated members of the Executive Committee will each co-lead specific project activities through specific working groups (e.g., Scoping review, protocol development, Public and Patient involvement) in consultation with the Executive Committee. Decisions or requests for input/feedback by the working groups to the Executive Committee will be communicated to the Executive Committee either at regular meetings or via email. These working groups will meet by webinar as required by the specific project activities until the task is complete. A small Project Team, which comprises of the Principal Investigator, the Trial methodologist, and the Clinical Trials Programme manager, will be tasked with the day-to-day management of the project and will meet weekly via webinar.

To provide independent oversight of the project, in particular the development of the Delphi survey and the Dose-Finding CONSORT extension guidelines prior to submission, an Independent Expert Panel has also been formed. Members include:

• Professor Elizabeth Garrett-Mayer [chair], American Society of Clinical Oncology, expert methodologist/trialist in dose-finding oncology trials.
• Professor Deborah Ashby, Imperial College London, expert methodologist/trialist in various diseases and was the independent chair of the ACE (Adaptive Designs) CONSORT extension.
• Professor John Isaacs, Newcastle University, expert clinician scientist in Rheumatology.

5 Methodology

To achieve these objectives, the Dose-finding consort development group will follow gold standard methods for developing healthcare reporting guidelines recommended by the CONSORT group [8].

5.1 Stage one: Draft checklist generation

5.1.1 Rapid Scoping Review

A rapid scoping review will be conducted in order to explore the current status of reporting of early phase dose-finding trials, identify any gaps and any specific features to dose-finding early phase trials not adequately covered by existing guidance, and to inform the drafting of the checklist. The review will also serve in providing a sampling frame for some of the stakeholder categories for the Delphi survey (see section 5.2). This rapid scoping review will be conducted in accordance with the Johanna Brings Institute (JBI) methodology for scoping reviews ([9]). Through 3 iterative phases (inclusion/exclusion, pilot run and main extraction), a total of 476 papers reporting early phase dose-finding trials published between 2011 and 2020, stratified by setting (oncology/non oncology) will be reviewed. To standardise the review process, a detailed data extraction form will be generated, and a comprehensive accompanying guidance document produced. Agreement between reviewers will also
be tested based on pre-established rules. The rapid scoping review will be the subject of a separate publication, and the protocol will be available upon request.

5.1.2 Candidate Item Generation

Based on the results of the rapid scoping review (see section 5.1.1) as well as expert opinion from the group, items considered to be relevant in constituting a minimum set of reporting requirements will be identified as potential checklist candidates. In addition, a further literature review of multiple databases (PubMed and Embase), grey literature and regulatory or industry guidelines, will be performed for any existing relevant guidance. Feedback will also be sought from regulatory bodies, such as the MHRA and FDA.

The Executive Committee will then meet to discuss the list of candidate items generated from these findings. Through expert discussion, the Executive committee will seek to build a comprehensive list of potentially important reporting items to design the first round of the Delphi survey. In case of disagreement on inclusion or exclusion of an item following discussion, decision may be subject to a majority vote amongst the Committee members. This/these meeting(s) will be audio recorded and detailed minutes will be kept, in order to inform the rationale for selection of items. Generated items will be presented in logical order to match the ordering of the existing CONSORT 2010 checklist[5].

5.2 Stage two: Delphi Survey

Once a draft checklist of potentially important items has been developed, it will be submitted for feedback by a wider stakeholder group through a Delphi survey. The objective of the Delphi survey is to gather stakeholders’ opinions on the importance of the drafted reporting items. The process will also gather feedback on any other aspect of reporting of early phase dose-finding trials the respondent feels is not covered by the proposed checklist through the use open-ended questions to allow free text feedback. The Delphi process will be conducted according to existing methodological guidance [10-12]) and will involve inviting participants to complete iterative rounds of a web-based survey, where results from earlier rounds will inform the design of subsequent rounds and modify the design between rounds. It is anticipated the Delphi process will be completed in 2-3 rounds, and the Executive Committee will meet between each round to discuss the results and agree any required changes.

5.2.1 Identification of participants

A wide cross section of stakeholders will be approached to take part in the Delphi survey. In the context of this study, stakeholders will be considered to be direct users or beneficiaries of the guidance and those involved in research governance, approval, commissioning or publishing and are deemed to fall in at least one of these categories:

- a) clinical trials researchers who have been involved in early phase dose-finding trials, have some knowledge and interest in early phase dose-finding trials, developed or have experience in conducting and reporting such trials. These include clinicians trial statisticians, trial methodologists, trial/study managers,
- b) assessors and approvers of clinical trials such as regulatory assessors and ethics committees,
- c) beneficiaries or users of the resultant CONSORT guidance such as journal editors,
- d) commissioners of research grants such as funders,
- e) consumers of research results from early phase dose-finding trials and assessors of quality of evidence from such trials such as abstract reviewers,
- f) healthy volunteers, patients and patient representatives with experience of early phase dose-finding trials.

Potential participants will be approached through a combination of named and blind approaches through publicly available contact details and various professional organisations or advocacy groups, as referenced in Table 1 below.

Table 1: Delphi survey stakeholders and methods of access

<table>
<thead>
<tr>
<th>Stakeholders</th>
<th>Platforms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials Researchers:</td>
<td>• MRC-NIHR TMRP (UK)</td>
</tr>
<tr>
<td>Clinicians</td>
<td>• UK Clinical Research Collaboration (CRC) Network of Registered CTUs</td>
</tr>
<tr>
<td>Trial management staff</td>
<td>• Targeted conferences or organisations such as Society for Clinical Trials,</td>
</tr>
<tr>
<td>Clinicians</td>
<td>International Clinical Trials Methodology Conference (ICTMC),</td>
</tr>
<tr>
<td>Statisticians</td>
<td>International Society for Clinical Biostatistics (ISCB),</td>
</tr>
<tr>
<td>Trial methodologists</td>
<td>Statisticians in the Pharmaceutical Industry (PSI), European Federation of Statistics in the Pharmaceutical Industry (EFSPI), Drug Information association (DIA)</td>
</tr>
<tr>
<td></td>
<td>• Clinical Conferences such as NCRI, ESMO, ASCO, ECMC, ECRD</td>
</tr>
<tr>
<td></td>
<td>• Sponsors from industry (via organisations such as Pharmaceutical Research and Manufacturers of America (PhRMA) in US, European Federation of Pharmaceutical Industries and Associations (EFPIA) in Europe) or the Association of British Pharmaceutical Industry (ABPI)</td>
</tr>
<tr>
<td></td>
<td>• Publications (including corresponding authors of papers selected through the Scoping review process)</td>
</tr>
<tr>
<td></td>
<td>• Executive Committee members professional contacts</td>
</tr>
<tr>
<td></td>
<td>• Targeted professional social network groups</td>
</tr>
<tr>
<td>Regulators</td>
<td>• US Food and Drug Administration (FDA)</td>
</tr>
<tr>
<td></td>
<td>• European Medicines Agency (EMA)</td>
</tr>
<tr>
<td></td>
<td>• UK Medicines and Healthcare products Regulatory Agency (MHRA),</td>
</tr>
<tr>
<td></td>
<td>• Japan Pharmaceuticals and Medical Devices Agency (PMDA)</td>
</tr>
<tr>
<td></td>
<td>• China National Medical Product Association Centre for Drug Evaluation</td>
</tr>
<tr>
<td></td>
<td>(NMPA CDE)</td>
</tr>
<tr>
<td></td>
<td>• Australia Therapeutic Group Administration (TGA)</td>
</tr>
<tr>
<td></td>
<td>• Drugs Controller General of India (DCGI)</td>
</tr>
<tr>
<td></td>
<td>• Health Products and Food Branch (HPFB), Health Canada.</td>
</tr>
<tr>
<td></td>
<td>• Ministry of Food and Drug Safety, South Korea.</td>
</tr>
<tr>
<td></td>
<td>• Executive Committee members professional contacts</td>
</tr>
<tr>
<td>Ethics Committee</td>
<td>• UK Health Research Authority (HRA) (targeting RECS specialised in reviewing early phase trials).</td>
</tr>
<tr>
<td></td>
<td>• EUREC (European Network of ethics Committees)</td>
</tr>
<tr>
<td></td>
<td>• US Institutional Review Boards</td>
</tr>
<tr>
<td></td>
<td>• Australia Health Research Ethics Committees registered through the National Human Medical Research Council.</td>
</tr>
<tr>
<td></td>
<td>• India Institutional Ethics Committees</td>
</tr>
</tbody>
</table>
| Journal editors, associate editors and Conference Abstracts Committee Members | • Leading medical research journals in publishing clinical trials, and targeted journals will be informed by journal where many Phase I trials have been published (identified through scoping review)  
• International Committee of Medical Journal Editors (ICMJE)  
• Abstract Committee members from leading conferences presenting Phase 1 results (see above).  
• Executive Committee members professional contacts |
| --- | --- |
| Funders | • Funding panels such as MRC, NIHR, CRUK, Blood Cancer UK, Wellcome Trust, Melinda and Bill Gates Foundation, Great Ormond Street Hospital and other selected charities funding phase 1 work as applicable  
• USA NIH  
• Pharmaceutical companies  
• Executive Committee members professional contacts |
| Patients and Public | • Patient and Public engagement platforms  
• European Patients’ forum [https://www.eu-patient.eu/](https://www.eu-patient.eu/)  
• International disease specific advocacy groups  
• Patient representatives on Phase 1 trials management groups (through CTUs portfolios)  
• Executive Committee members’ professional contacts |

The survey will also be advertised on social media and a link to the survey will be provided on the DF-CONSORT website ([https://www.icr.ac.uk/dosefindingconsort](https://www.icr.ac.uk/dosefindingconsort)).

### 5.2.2 Consent, withdrawal and confidentiality

Consent to take part in the Delphi survey will be sought from every participant via the web-based survey application. No personal identifiable data will be collected aside from name and email address. Data gathered will include professional background characteristics of participants, including geographical location and self-identified stakeholder group (as defined in section 5.2.1 above). Information on data processing and handling will be provided on the website prior to consent.

Data from the survey will be stored on a secure, access restricted server at ICR-CTSU and in accordance with all applicable data protection laws. Participants will be able to withdraw at any point, however data collected up to the point of withdrawal will be kept unless deletion is specifically requested.

### 5.2.3 Sample size

As a prospective exercise and a multi-faceted survey, it is difficult to ascribe a defined sample size. However, in order to ensure meaningful representation of all the stakeholder categories, the survey will seek to obtain responses from at least 15 participants in each of the identified stakeholder categories to all survey rounds. To achieve this, and anticipating an attrition rate between 20 and 40%, 20 - 25 per category will need to be registered, a total of 105-140 overall. To achieve this, as many potential participants as possible will be approached. The registration and response rates will be
monitored by the Executive Committee, who may decide to invite further potential participants if required.

5.2.4 Scoring

Each candidate item will be scored on a 9-point Likert scale relating to the participant’s opinion of its importance. Unsure or Don’t know / not my expertise options will be provided for participants who are unable to give their rating opinions for any reasons. Free text fields will also be used to elicit comments on the candidate items, and in round one to invite potential additional reporting items, which may have been missed or considered less important previously.

5.2.5 Software

After a review of the platforms available, the Project Team will confirm the software to be used to run the Delphi Survey.

5.2.6 Survey administration

Potential participants will be approached as described in the table above and recipients of the invitation will be encouraged to forward the invitation to other potentially interested stakeholders. A combination of named and blind approaches will be used, where pre-selected named potential participants will be invited to take part and nominate additional experts to be contacted by the DF-CONSORT team, and various professional or advocacy groups will be approached for dissemination amongst their members. Interested stakeholders will be asked to register on the survey website prior to the survey launch. For named approaches, a follow-up to the initial invite will be sent week before the survey launch. Once registered, consented participants will be alerted to the survey launch by an email containing the link to the survey. Each round of the survey will be opened for 4-weeks and reminders will be sent weekly during this period. Participants will be allowed to complete a round even if they haven’t completed the previous one.

5.2.7 Pilot

Following an informal pilot round amongst volunteers of the executive committee to troubleshoot any obvious issues, the survey will undergo a formal pilot phase to check for any issues with technical functionality, wording, logical flow or any other concerns, before launching the main survey. This pilot will be performed by a small number of stakeholders independent from the Executive Committee, who will aim to select at least 2 pilot participants from the following key stakeholder categories: clinician, statistician, trial manager and patient/healthy volunteer. As an additional option, regulators and a further key category may be included.

Pilot participants will be provided with the tracked changes to the candidate items following the pilot and offered the opportunity to complete the survey again once. Pilot or amended responses, as appropriate, will be included into the first round of the survey.

5.2.8 Analysis

The response observed for the initial blind and named approaches will be explored in a narrative summary. Following each round, response rate will be calculated based on the number of participants registered and having completed the survey. For each item, distribution of scores as well as mean, maximum and minimum, SD variance will be computed and graphically presented. Summary statistics will be presented by the key stakeholder categories defined in section 5.3.3 and overall, and the
geographical and professional background characteristics data collected (see 5.2.2 Consent, withdrawal and confidentiality above) may be used to explore the data further if relevant.

Qualitative data from the free text section of the survey will be thematically analysed to identify potential new items for inclusion.

After each round, members of the Executive Committee will be sent the results of the survey individually, prior to meeting (via video conference) to discuss the output and any changes required. Notes will also be made of any feedback relevant to the development of the E&E document. Additionally, the Executive Committee may decide to increase the number of participants, either overall or in certain stakeholder categories, based on observed response rates.

Reports summarising the Delphi results will be produced and circulated to all participants after each round. Participants will also be presented with their own ratings from the previous round, as well as feedback on how suggestions and comments from the free text fields were dealt with. The Executive Committee will decide on the most appropriate format, content and manner of dissemination for these reports.

At further rounds, participants will be given the opportunity to change their ratings, and such changes will be monitored. The change in participants’ ratings between subsequent rounds will be analysed at item level and interest will be on participants who changed:

1) 1-6 ‘not important’ or ‘important, but not critical’ in round 1 to 7-9 in round 2 ‘critically important’,
2) 7-9 ‘critically important’ in round 1 to 1-6 ‘not important’ or ‘important, but not critical’ in round 2,
3) 1-3 ‘not important’ in round 1 to 4-6 ‘important, but not critical’ in round 2,
4) 4-6 ‘important, but not critical’ in round 1 to 1-3 ‘not important’ in round 2.

For each reporting item, the distribution of the changes in rating scores and proportion below 15% change will be reported.

To gauge the level of agreement between round 1 and round 2 ratings, the following statistics will be calculated and reported for each reporting item with associated 95% confidence intervals [13]:

a) percentage agreement; percentage of participants with the same rating between rounds relative to the total responders to all rounds,

b) weighted Cohen’s kappa coefficient using absolute error weights. [14].

The analysis will be performed in R.

5.2.9 Stopping Criteria

The Executive Committee will decide to stop the Delphi Survey process once consensus and stability of ratings have been achieved. It is anticipated that 2 rounds will be sufficient to achieve this objective, however, the Committee may proceed to a third round based on the observed level of agreement, and an assessment on whether a subsequent round is likely to yield any further information. The Executive committee will make a decision based on their review of the Delphi survey results as
described above and assess whether sufficient agreement and stability have been reached, aided by the stability and agreement criteria defined above.

5.3 Stage 3: Consensus Meeting:

5.3.1 Objectives

The objectives of the Consensus meeting will be to discuss and finalise the full list of items to be included in the guidance, guided by the information on item importance and level of agreement gleaned during the Delphi survey process, as well as the structure of the E&E document.

5.3.2 Definition of Consensus

For the purpose of automatic inclusion into the checklist, items rated 7-9 (“Critically Important”) by at least 70% of the Delphi survey respondents will be considered as having reached consensus.

5.3.3 Identification of participants

The Executive Committee will discuss and produce a list of experts in each of the key stakeholder categories described above to be approached for participation in the consensus meeting. If necessary, the Independent Expert Panel, as well as other professional groups may be approached to suggest potential candidates, subject to the Executive Committee sanction. The consensus meeting will be chaired by Professor Deborah Ashby.

5.3.4 Consensus meeting activities

The Executive Committee will prepare the agenda and meeting documentation to be shared with participants prior to the meeting, to include the results of the Delphi survey and the draft items checklist. The Consensus meeting will follow the recommended methodology for such exercise [8]. At the meeting Executive Committee members will first present the background and an update on work done to date, in order to facilitate the discussions. Session chairs then separately present items from the preliminary checklist, results of the Delphi study and feedback from stakeholders. Checklist items having reached consensus (see section 5.3.2) will be automatically recommended for inclusion. Items that did not reach consensus will be discussed for inclusions and/or modification based on the overall importance rating achieved in the last round of the Delphi Survey. Following the discussion, consensus group members will anonymously be given an opportunity to make individual decisions about the inclusion of a specific item; ‘keep’, ‘discard’, and ‘unsure or no opinion’. A decision to retain a reporting item will be based on achieving at least 50% support of group members deciding/wishing to keep the item. The rationale to guide decisions will be whether the item addresses elements unique to dose-finding early phase trials and whether they belonged in a minimum reporting set of items. Notes will be taken, and the discussions audio-recorded, with the participants’ consent. Particular attention will be paid to any feedback or discussion requiring inclusion in the E&E document.

Following the meeting, a summary report will be produced and shared with the meeting attendees, as well as the Delphi survey participants.

5.4 Stage 4: Development of a reporting guidance and explanatory support document
5.4.1 Guideline development process

After the consensus meeting, the Executive Committee will continue working on refining the content and wording of the guidance, as well as preparing a detailed explanation and elaboration document. Feedback from the Delphi survey and the consensus meeting will be checked for any information relevant for inclusion in the E&E document.

The E&E document is intended to provide detailed explanation on the rationale for inclusion of the items, as well as evidence and examples applied in the literature.

5.4.2 Piloting the guideline

The guideline will be piloted by a small selection of key stakeholders with expertise in developing and reporting early phase dose-finding trials to test its usability and provide insight into issues that should be addressed in detail in the Explanation & Elaboration statement. As part of the guideline development process, the Executive committee will decide on the most appropriate piloting strategy and potential stakeholders to be invited to pilot the checklist. The Committee will discuss feedback from the pilot and decide on whether further modifications are required, either to the checklist itself or the E&E document.

6 Stage 5: Dissemination plan

The Executive Committee will devise a detailed dissemination strategy to maximise guideline awareness and uptake. Broadly, the strategy will comprise of the following:

- Direct feedback will be provided to the Delphi Survey participants, Consensus meeting contributors and the stakeholders groups identified in Table 1.
- The guideline will be accessible via the CONSORT and EQUATOR network websites, as well as on the DF-CONSORT project’s own website, which will also be kept updated throughout the project.
- Dissemination at specific UK and international study groups that run Phase I trials, such as the UK National Cancer Studies Groups, as well as to funders for early phase trials (including MRC, CRUK, NIHR BRCs, ECMC and NCI), and to industry via The Association of British Pharmaceutical Industry (ABPI) and pharma partners’ networks.
- Maximising publications in high impact scientific journals.
- Presentation at meetings of UK Clinical Research Collaboration (UKCRC) Clinical Trials Unit, UKCRC Statistics Operational Group and NIHR Early Phase Statistics Group; national and international methodological conferences (e.g. International Clinical Trials and Methodology Conference, Society of Clinical Trials or International Society of Clinical Biostatistics), and at pharmaceutical conferences/meetings via our industry partners (e.g. PSI, EFPSI, DIA) and clinical conferences (e.g. NCRI, ESMO, ASCO, ECRD).
- Practical Dissemination workshops will be organised, one specifically aimed at journal editors in order to promote use of the guideline and encourage endorsement.
- Patient and public engagement will also be sought via the publication of two PPI lay summary papers, liaison with patients’ groups (including the Royal Marsden Patients and Carers Review Panel and the Independent Cancer Patient’s Voice), as well as dissemination at local and national PPI events.
- Broader communication with the public will also be pursued via the Institute of Cancer Research’s website and social media, including blogs, posts on Twitter, Facebook and LinkedIn, press releases and potentially thought leadership pieces on trials reporting in the media.

7 Ethics approval

This project has been formally assessed for risk and approved by the Sponsor’s Committee for Clinical Research. The Heath Research Authority has been consulted and confirmed Research Ethics Approval is not required.

8 Funding and any additional support

This project was funded through the UKRI’S MRC-NIHR funding stream through grant reference MR/T044934/1. The funders have no involvement in the study design, collection, analysis, interpretation of findings, and reporting. However, research outputs will be published in line with the funders’ publication policy requirements.

9 Declaration of Conflict of Interest

All Protocol Development Group members declare that they have no conflict of interest to disclose.
References